There are currently 148 active clinical trials seeking participants for Melanoma research studies. The states with the highest number of trials for Melanoma participants are California, Texas, Florida and Pennsylvania.
A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma
NCT04567706
Recruiting
This study collects and stores blood and tumor samples from patients with malignant melanoma and healthy individuals. The purpose of this study is to gain a better understanding of the causes of melanoma and how melanoma tumors behave. Storing blood and tumor samples for future research may lead to new discoveries that may ultimately help with diagnosing or treating this disease.
Gender:
All
Ages:
All
Trial Updated:
03/07/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Melanoma
Register for Updates
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
NCT06287463
Recruiting
This is a multicenter, Phase 1/2 clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with solid tumors. Additional modules exploring other cancers may be added to the master protocol at a later date. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, California +5 locations
Conditions: Advanced Solid Tumor, RAF Mutation, RAS Mutation, NF1 Mutation, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Melanoma, BRAF Gene Mutation, CRAF Gene Mutation
Register for Updates
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
NCT06326411
Recruiting
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: NEXT Oncology - Austin, Austin, Texas +7 locations
Conditions: Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation, Melanoma, NSCLC, Glioma, Solid Tumor, Adult, MAPK Pathway Gene Mutation
Register for Updates
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
NCT05355701
Recruiting
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines (called binimetinib) in people with solid tumors. This study is seeking participants who have an advanced solid tumor with a certain type of abnormal gene called "BRAF" and available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799933... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
06/20/2024
Locations: Highlands Oncology Group, Fayetteville, Arkansas +44 locations
Conditions: Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma
Register for Updates
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
NCT05053230
Recruiting
The overarching long-term goal of the Integrative Medicine for Patient-reported Outcomes Values and Experience (IMPROVE) research program is to evaluate whether integrating a virtual mind-body programming, Integrative Medicine at Home (IM@Home), will improve patient perceived values, outcomes, and experiences as they undergo systemic cancer treatment such as chemotherapy, immunotherapy, radiotherapy, targeted agents, cytoreductive surgery.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Head and Neck Cancer, Head and Neck Tumor, Thoracic Tumor, Thoracic Cancer, Gynecologic Cancer, Gynecologic Tumor, Melanoma, Ovarian Cancer
Register for Updates
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
NCT04955743
Recruiting
This is a phase 2, Simon's 2-stage designed study with 2 cohorts of anti-PD-1/PD-L1 experienced patients with untreated brain metastases: 1) melanoma and 2) renal cell carcinoma (RCC).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Melanoma, Renal Cell Carcinoma, Brain Metastases, PD1/PD-L1 Experienced, Pembrolizumab, Lenvatinib, Metastatic Melanoma
Register for Updates
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
NCT05907122
Recruiting
The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
06/19/2024
Locations: Cancer and Blood Specialty Clinic, Long Beach, California +109 locations
Conditions: Melanoma
Register for Updates
A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577
Recruiting
The purpose of this study is to learn if V940 which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Highlands Oncology Group ( Site 1943), Springdale, Arkansas +148 locations
Conditions: Melanoma
Register for Updates
Evaluation for NCI Surgery Branch Clinical Research Protocols
NCT00001823
Recruiting
Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols. Eligibility: Patients 18 years or older must meet the minimum eligibility criteria for an NCI-SB treat... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Synovial Cell Cancer, Melanoma, Colorectal Cancer, Lung Cancer, Bladder Cancer
Register for Updates
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
NCT02910557
Recruiting
A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients, close contacts, and health care providers; and long term safety in treated patients for up to 5 years after the first IMLYGIC dose.
Gender:
All
Ages:
All
Trial Updated:
06/19/2024
Locations: Mercy Medical Center, Baltimore, Maryland +20 locations
Conditions: Melanoma, Herpetic Infection
Register for Updates
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
NCT06054555
Recruiting
The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
06/19/2024
Locations: Cancer and Blood Specialty Clinic, Long Beach, California +99 locations
Conditions: Melanoma
Register for Updates
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
NCT04609566
Recruiting
This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic). The study will also find out what side effects occur. A side effect is anything the treatment does besides treat cancer. This is a multi-cohort study.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Arizona Oncology Associates, PC - HOPE, Tucson, Arizona +34 locations
Conditions: Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Register for Updates